ProQuadTreatment for Measles Prophylaxis, Mumps Prophylaxis, Rubella Prophylaxis, Varicella-Zoster -- Prophylaxis
Merck Files Biologics License Application for Proquad With U.S. Food and Drug Administration
WHITEHOUSE STATION, N.J.--November 4, 2004 - Merck & Co., Inc. today announced it has filed a Biologics License Application for Proquad (Measles, Mumps, Rubella and Varicella (Oka/Merck) Virus Vaccine Live) with the U.S. Food and Drug Administration.
Proquad is an investigational vaccine for simultaneous vaccination against measles, mumps, rubella and varicella in children 12 months to 12 years of age. Proquad combines two established Merck vaccines, M-M-R II (Measles, Mumps, Rubella Virus Vaccine Live) and Varivax (Varicella (Oka/Merck) Virus Vaccine Live).
Merck submitted the application for Proquad to the FDA on Aug. 31 and received notification of the FDA's acceptance of the application this week. Merck anticipates an FDA action on the application by early July, based on a standard 10 to 12-month FDA review.
Important information about M-M-R II and Varivax
M-M-R II is indicated for simultaneous vaccination against measles, mumps and rubella in individuals 12 months of age or older. The Advisory Committee on Immunization Practices (ACIP) recommends administration of the first dose of M-M-R II at 12 to 15 months of age and administration of the second dose of M-M-R II at four to six years of age. M-M-R II is contraindicated in individuals with a history of hypersensitivity to any component of the vaccine, including gelatin. M-M-R II is contraindicated in individuals with blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the bone marrow or lymphatic systems. Due caution should be employed in administration of M-M-R II to persons with a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided. The following adverse reactions, which have been reported without regard to causality, include: fever, headache, dizziness, rash, injection-site reactions, anaphylaxis and anaphylactoid reactions, thrombocytopenia, arthritis and febrile convulsions. For a list of adverse reactions, please see the M-M-R II Prescribing Information. As for any vaccine, vaccination with M-M-R II may not result in protection in 100 percent of vaccinees.
Varivax is indicated for vaccination against varicella in individuals 12 months of age and older. Varivax is contraindicated in individuals with a history of hypersensitivity or an anaphylactoid reaction to any component of the vaccine, including gelatin or neomycin, or with any immunodeficient condition or receiving immunosuppressive therapy. The duration of protection from varicella infection after vaccination with Varivax is unknown. There are insufficient data to assess the rate of protection against the complications of varicella (e.g., encephalitis, hepatitis, pneumonia) in children. In children, adolescents and adults monitored for up to 42 days post vaccination, the adverse effects most frequently reported were as follows: fever, injection-site complaints; varicella-like rash (injection site) and varicella-like rash (generalized). For a list of adverse reactions, please see the Varivax Prescribing Information. Vaccination with Varivax may not result in protection of all healthy susceptible children, adolescents and adults.
Merck & Co., Inc. is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures.
Posted: November 2004
- Proquad Merck & Co., Inc. - Treatment for Measles, Mumps, Rubella and Varicella Vaccination - September 6, 2005